Novocure [NVCR] vs Enovis [ENOV] Detailed Stock Comparison
Novocure
NASDAQ
Loading...
Enovis
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Novocure wins in 7 metrics, Enovis wins in 11 metrics, with 0 ties. Enovis appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Novocure | Enovis | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -7.13 | -1.90 | Novocure |
| Price-to-Book Ratio | 3.56 | 0.63 | Enovis |
| Debt-to-Equity Ratio | 200.39 | 56.75 | Enovis |
| PEG Ratio | -7.42 | 9.00 | Novocure |
| EV/EBITDA | -6.50 | 8.41 | Novocure |
| Profit Margin (TTM) | -27.13% | -37.80% | Novocure |
| Operating Margin (TTM) | -24.89% | 2.41% | Enovis |
| EBITDA Margin (TTM) | N/A | 2.41% | N/A |
| Return on Equity | -48.07% | -28.25% | Enovis |
| Return on Assets (TTM) | -8.64% | 0.89% | Enovis |
| Free Cash Flow (TTM) | $-69.22M | $-67.21M | Enovis |
| 1-Year Return | -40.45% | -34.47% | Enovis |
| Price-to-Sales Ratio (TTM) | 2.04 | 0.74 | Enovis |
| Enterprise Value | $1.03B | $3.05B | Enovis |
| EV/Revenue Ratio | 1.64 | 1.39 | Enovis |
| Gross Profit Margin (TTM) | 73.88% | 59.45% | Novocure |
| Revenue per Share (TTM) | $6 | $39 | Enovis |
| Earnings per Share (Diluted) | $-1.51 | $-14.95 | Novocure |
| Beta (Stock Volatility) | 0.61 | 1.81 | Novocure |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Novocure vs Enovis Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Novocure | -3.30% | -1.68% | -36.44% | -36.18% | -48.59% | -62.89% |
| Enovis | -0.28% | 10.49% | -18.13% | -14.03% | -36.06% | -35.80% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Novocure | -40.45% | -87.05% | -85.30% | -39.11% | -39.11% | -39.11% |
| Enovis | -34.47% | -52.47% | -52.16% | -58.10% | 33.33% | -19.39% |
Performance & Financial Health Analysis: Novocure vs Enovis
| Metric | NVCR | ENOV |
|---|---|---|
| Market Information | ||
| Market Cap | $1.29B | $1.63B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 2,472,605 | 1,375,280 |
| 90 Day Avg. Volume | 1,827,595 | 1,733,377 |
| Last Close | $11.13 | $28.44 |
| 52 Week Range | $10.91 - $34.13 | $25.47 - $49.83 |
| % from 52W High | -67.39% | -42.93% |
| All-Time High | $232.76 (Jun 21, 2021) | $129.72 (Jun 09, 2014) |
| % from All-Time High | -95.22% | -78.08% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.06% | 0.08% |
| Quarterly Earnings Growth | 0.06% | 0.08% |
| Financial Health | ||
| Profit Margin (TTM) | -0.27% | -0.38% |
| Operating Margin (TTM) | -0.25% | 0.02% |
| Return on Equity (TTM) | -0.48% | -0.28% |
| Debt to Equity (MRQ) | 200.39 | 56.75 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $3.13 | $45.11 |
| Cash per Share (MRQ) | $8.15 | $0.77 |
| Operating Cash Flow (TTM) | $-44,676,000 | $188.06M |
| Levered Free Cash Flow (TTM) | $5.94M | $65.68M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | $0.00 |
Valuation & Enterprise Metrics Analysis: Novocure vs Enovis
| Metric | NVCR | ENOV |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -7.13 | -1.90 |
| Forward P/E | -7.42 | 9.00 |
| PEG Ratio | -7.42 | 9.00 |
| Price to Sales (TTM) | 2.04 | 0.74 |
| Price to Book (MRQ) | 3.56 | 0.63 |
| Market Capitalization | ||
| Market Capitalization | $1.29B | $1.63B |
| Enterprise Value | $1.03B | $3.05B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.64 | 1.39 |
| Enterprise to EBITDA | -6.50 | 8.41 |
| Risk & Other Metrics | ||
| Beta | 0.61 | 1.81 |
| Book Value per Share (MRQ) | $3.13 | $45.11 |
Financial Statements Comparison: Novocure vs Enovis
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NVCR | ENOV |
|---|---|---|
| Revenue/Sales | $154.99M | $558.83M |
| Cost of Goods Sold | $38.52M | $226.61M |
| Gross Profit | $116.47M | $332.23M |
| Research & Development | $53.78M | $28.53M |
| Operating Income (EBIT) | $-37.87M | $-42.91M |
| EBITDA | $-34.54M | $27.14M |
| Pre-Tax Income | $-30.30M | $-57.35M |
| Income Tax | $4.02M | $-1.77M |
| Net Income (Profit) | $-34.32M | $-55.71M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NVCR | ENOV |
|---|---|---|
| Cash & Equivalents | $127.28M | $38.46M |
| Total Current Assets | $1.09B | $1.22B |
| Total Current Liabilities | $743.31M | $477.42M |
| Long-Term Debt | $137.76M | $1.42B |
| Total Shareholders Equity | $361.96M | $2.62B |
| Retained Earnings | $-1.19B | $-338.99M |
| Property, Plant & Equipment | $145.02M | $492.24M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NVCR | ENOV |
|---|---|---|
| Operating Cash Flow | $-14.80M | $-1.07M |
| Capital Expenditures | $-10.61M | $-43.26M |
| Free Cash Flow | $-46.28M | $-44.86M |
| Debt Repayment | $0 | $-15.44M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | NVCR | ENOV |
|---|---|---|
| Shares Short | 4.93M | 7.43M |
| Short Ratio | 3.87 | 4.68 |
| Short % of Float | 0.07% | 0.20% |
| Average Daily Volume (10 Day) | 2,472,605 | 1,375,280 |
| Average Daily Volume (90 Day) | 1,827,595 | 1,733,377 |
| Shares Outstanding | 108.52M | 55.88M |
| Float Shares | 94.16M | 56.44M |
| % Held by Insiders | 0.10% | 0.02% |
| % Held by Institutions | 0.79% | 1.08% |
Dividend Analysis & Yield Comparison: Novocure vs Enovis
| Metric | NVCR | ENOV |
|---|---|---|
| Last 12-Month Dividend | N/A | $0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | $0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | $0.00 |
| Ex-Dividend Date | N/A | N/A |